Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0288006 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Thailin Lao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genetic Engineering and Biotechnology, Animal Biotechnology Department, Havana, Cuba. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite that more than one hundred vaccines against SARS-CoV-2 have been developed and that some of them were evaluated in clinical trials, the latest results revealed that these vaccines still face great challenges. Among the components of the virus, the N-protein constitutes an attractive target for a subunit vaccine because it is the most abundant, highly conserved and immunogenic protein. In the present work, a chimeric protein (N-CD protein) was constructed by the fusion of the N-protein to the extracellular domain of human CD154 as the molecular adjuvant. HEK-293 cells were transduced with lentiviral vector bearing the N-CD gene and polyclonal cell populations were obtained. The N-CD protein was purified from cell culture supernatant and further characterized by several techniques. Immunogenicity studies in mice and non-human primates showed the N-CD protein induced high IgG titers in both models after two doses. Moreover, overall health monitoring of non-human primates demonstrated that animals were healthy during 228 days after first immunization. Data obtained support further investigation in order to develop this chimeric protein as vaccine candidate against COVID-19 and other coronavirus diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Genetic Engineering and Biotechnology, Animal Biotechnology Department, Havana, Cuba.
- Center for Genetic Engineering and Biotechnology, Laboratory of Molecular Oncology, Havana, Cuba.
- Center for Genetic Engineering and Biotechnology, Systems Biology, Havana, Cuba.
- Center for Genetic Engineering and Biotechnology, Animal housing, Havana, Cuba.
- Center for Genetic Engineering and Biotechnology, Production Division, Havana, Cuba.
Zitieren
APA
Lao, T., Avalos, I., Rodríguez, E. M., Zamora, Y., Rodriguez, A., Ramón, A., Alvarez, Y., Cabrales, A., Andújar, I., González, L. J., Puente, P., García, C., Gómez, L., Valdés, R., Estrada, M. P., & Carpio, Y. (2023). Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19. PLOS ONE. https://doi.org/10.1371/journal.pone.0288006
Vancouver
Lao T, Avalos I, Rodríguez EM, Zamora Y, Rodriguez A, Ramón A, et al. Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19. PLOS ONE. 2023. doi:10.1371/journal.pone.0288006
BibTeX
@article{Lao2023,
author = {Lao, Thailin and Avalos, Ileanet and Rodríguez, Elsa María and Zamora, Yasser and Rodriguez, Alianet and Ramón, Ailyn and Alvarez, Yanitza and Cabrales, Ania and Andújar, Ivan and González, Luis Javier and Puente, Pedro and García, Cristina and Gómez, Leonardo and Valdés, Rodolfo and Estrada, Mario Pablo and Carpio, Yamila},
title = {Production and characterization of a chimeric antigen, based on nucleocapsid of SARS-CoV-2 fused to the extracellular domain of human CD154 in HEK-293 cells as a vaccine candidate against COVID-19},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0288006}
}
EUVIMED